I wouldn't be surprised if CHF is partnered up relatively soon...

I wouldn't be surprised if CHF is partnered up relatively soon either.. the chance of accelerated approval / breakthrough designation after the FDA meeting is also quite possible. The FDA indicated to Mesoblast that approval from a single trial could be given if a mortality benefit was achieved, and that is exactly what the phase 3 trial showed in Class II patients.

Silviu has always insisted that Rex-L would be a complementary treatment to existing and newly approved therapies (such as Novartis' Entresto) which have had great success in reducing repeat hospitilisations due to volume overload, but have only had less than 20% reduction in mortality (vs Rex-L's 60% reduction).